Zobrazeno 1 - 10 of 25 pro vyhledávání: '"Diana J. Griffith"'
1
Supplementary Figures 1-4 and Supplementary Tables 1-3 from Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity
Autor: Michael C. Heinrich, Ajia Town, Carol Beadling, Diana J. Griffith, Janice Patterson, Lillian R. Klug, Alison C. Macleod
Figure S1: HMC1.2 cell line has constitutively actived NFAT2, NFAT2 and NFAT4 species; Figure S2: RT-PCR of transcripts modulated by 24 hour treatment with CSA; Figure S3: CNPIs do not modulate KIT signaling and KIT inhibitors do not affect NFAT loca
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e518f583acccdf8a901bb064a3d220b
https://doi.org/10.1158/1535-7163.22500676
Zobrazit plný text záznamu
2
Data from Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity
Autor: Michael C. Heinrich, Ajia Town, Carol Beadling, Diana J. Griffith, Janice Patterson, Lillian R. Klug, Alison C. Macleod
Resistant KIT mutations have hindered the development of KIT kinase inhibitors for treatment of patients with systemic mastocytosis. The goal of this research was to characterize the synergistic effects of a novel combination therapy involving inhibi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16ae29e89fef41b4d92af10f6b06768c
https://doi.org/10.1158/1535-7163.c.6536539.v1
Zobrazit plný text záznamu
4
Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity
Autor: Alison C. Macleod, Janice Patterson, Lillian R. Klug, Diana J. Griffith, Carol Beadling, Ajia Town, Michael Heinrich
Publikováno v: Molecular Cancer Therapeutics. 13:2840-2851
Resistant KIT mutations have hindered the development of KIT kinase inhibitors for treatment of patients with systemic mastocytosis. The goal of this research was to characterize the synergistic effects of a novel combination therapy involving inhibi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21a4ff0f6cd8cce76af92f72913c7fb
https://doi.org/10.1158/1535-7163.mct-13-0830
Zobrazit plný text záznamu
5
Creation and characterization of a novel human PDGFRA D842V-mutant GIST cell line
Autor: Sebastian Bauer, Gleb Abalakov, Susanne Grunewald, Lillian R. Klug, Diana J. Griffith, Arin McKinley, Ajia Town, Lori Rink, Michael Heinrich
Publikováno v: Journal of Clinical Oncology. 37:e22512-e22512
e22512 Background: Activating PDGFRA mutations are seen in about 10% of gastrointestinal stromal tumors (GIST). Of these, the majority are one specific PDGFRA mutation, D842V, which confers resistance to all clinically approved tyrosine kinase inhibi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2648ea7b8ab6799a33fe90f207c970f4
https://doi.org/10.1200/jco.2019.37.15_suppl.e22512
Zobrazit plný text záznamu
6
Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
Autor: Diana J. Griffith, Janice Patterson, Abhijit Ramachandran, Arin McKinley, Maria Debiec-Rychter, Ajia Presnell, Michael Heinrich
Publikováno v: Clinical Cancer Research. 18:4375-4384
Purpose: To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA. Experimental Design: The biochemical activity of crenolanib was compared with imatinib using a panel of PDGFRA-mutant kina
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc0d345233da7044a509a08d2da25988
https://doi.org/10.1158/1078-0432.ccr-12-0625
Zobrazit plný text záznamu
7
Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors
Autor: Takahiro Taguchi, Rachel S. Donsky, Diana J. Griffith, Cher-Wei Liang, Ajia Presnell, Arin McKinley, Adrián Mariño-Enríquez, Michael Heinrich, Jonathan A. Fletcher, Janice Patterson
Publikováno v: Molecular Cancer Therapeutics. 11:1770-1780
Sorafenib has substantial clinical activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST). Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9c2bd8733cfa53611d9fbf1034850b8
https://doi.org/10.1158/1535-7163.mct-12-0223
Zobrazit plný text záznamu
8
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Autor: Christopher D.M. Fletcher, Wen-Bin Ou, Michael Heinrich, Robert G. Maki, Darrel P. Cohen, Arin McKinley, Jonathan A. Fletcher, Amy Harlow, Diana J. Griffith, Charles M. Baum, Christopher L. Corless, Ajia Town, George D. Demetri, Cristina R. Antonescu, Xin Huang
Publikováno v: Journal of Clinical Oncology. 26:5352-5359
PurposeMost gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated effica
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b3fcdd9df7bcee5125d375bdbcc984
https://doi.org/10.1200/jco.2007.15.7461
Zobrazit plný text záznamu
9
Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies
Autor: Amie S. Corbin, Marcus M Schittenhelm, Michael W. Deininger, Brian J. Druker, Michael Heinrich, Carsten Bokemeyer, Diana J. Griffith, Francis Y. Lee, Sharon Shiraga, Arin Schroeder
Publikováno v: Cancer Research. 66:473-481
Activating mutations of the activation loop of KIT are associated with certain human neoplasms, including the majority of patients with systemic mast cell disorders, as well as cases of seminoma, acute myelogenous leukemia (AML), and gastrointestinal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c48b481d3336a5cc4270ae9d7fe0c666
https://doi.org/10.1158/0008-5472.can-05-2050
Zobrazit plný text záznamu
10
Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kitProto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells
Autor: Michael Heinrich, Jay A. Nelson, Yolanda C. Bell, Ashlee V. Moses, Michael A. Jarvis, B. G. Mattias Luukkonen, Cecily L. Wait, Brian J. Druker, Klaus Früh, Rebecca Ruhl, Diana J. Griffith, Camilo Raggo
Publikováno v: Journal of Virology. 76:8383-8399
Kaposi's sarcoma (KS), the most frequent malignancy afflicting AIDS patients, is characterized by spindle cell formation and vascularization. Infection with KS-associated herpesvirus (KSHV) is consistently observed in all forms of KS. Spindle cell fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e036a7d85945d8b2c7d3e73ca22926
https://doi.org/10.1128/jvi.76.16.8383-8399.2002
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje